Search

Displaying results 5521 - 5530 of 9333 in total
  1. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. … It has been investigated for the treatment of hodgkin’s lymphoma.

  2. Drug

    Chikungunya virus Senegal strain 37997 capsid protein

    go.drugbank.com/drugs/DB21766
    ApprovedInvestigational

    One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

  3. Drug

    Chikungunya virus Senegal strain 37997 envelope protein E2

    go.drugbank.com/drugs/DB21768
    ApprovedInvestigational

    One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

  4. Drug

    Octacosanol

    go.drugbank.com/drugs/DB11220
    InvestigationalNutraceutical

    This high–molecular-weight organic compound is the main component of a natural product wax extracted from plants [A27245]. 1-octacosanol is reported to possess cholesterol-lowering effects, antiaggregatory … It has been studied as a potential therapeutic agent for the treatment of Parkinson's disease.

  5. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  6. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD). … It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease).

  7. Drug

    Ergosterol

    go.drugbank.com/drugs/DB04038
    ApprovedWithdrawn

    A steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result

  8. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749

    Synonyms: (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate, (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-Dimethyl-12-Oxo-2-[(2E,4E,6R)-6-(Pyridin-2-Yl)Hepta-2,4-Dien-2-Yl]Oxacyclododec-4-En-6-Yl 4-Methylpiperazine-1-Carboxylate
  9. Drug

    MVA-SARS-2-S

    go.drugbank.com/drugs/DB16432
    Investigational

    MVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines … MVA-SARS-2-S is a COVID-19 vaccine candidate that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein[L30453].

  10. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition